Mood enhancing supplement sales will grow through 2036, led by ashwagandha at an 18.6% share in 2026 as the leading ingredients segment. The market is expected to reach USD 758.4 million in 2026 and USD 933.6 million by 2036, creating an absolute dollar opportunity of USD 175.2 million.